Cover Image
市場調查報告書

全身性硬皮症(皮膚硬化症):開發平台分析

Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 213039
出版日期 內容資訊 英文 225 Pages
訂單完成後即時交付
價格
Back to Top
全身性硬皮症(皮膚硬化症):開發平台分析 Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2017
出版日期: 2017年07月18日 內容資訊: 英文 225 Pages
簡介

所謂皮膚硬化症是皮膚和結締組織硬化的難治之症之一。主要的症狀有肌肉痛和關節痛,腫脹(膿腫),指尖出現潰瘍,腹部膨脹,腹瀉·便秘等。主要的治療藥有抗生素和止痛藥,免疫抑制劑等。

本報告提供全球各國的全身性硬皮症治療用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

全身性硬皮症概要

治療藥的開發

  • 全身性硬皮症開發中產品:概要
  • 全身性硬皮症開發中產品:比較分析

各企業正在開發的全身性硬皮症治療藥

大學/研究機關研究中的全身性硬皮症治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 不明確的階段有的產品

全身性硬皮症治療藥:開發中的產品一覽(各企業)

全身性硬皮症治療藥:研究中的產品一覽(大學/研究機關別)

全身性硬皮症開發治療藥的企業

  • Allergan Plc
  • Angion Biomedica Corp.
  • arGentis Pharmaceuticals, LLC
  • Bayer AG
  • BioLineRx, Ltd.
  • BiOrion Technologies B.V.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Corbus pharmaceuticals, Inc.
  • CSL Limited
  • Daval International Limited
  • Digna Biotech, S.L.
  • F. Hoffmann-La Roche Ltd.
  • Fibrocell Science, Inc.
  • GenKyoTex S.A.
  • GlaxoSmithKline Plc
  • iBio, Inc.
  • Inventiva SAS
  • Kadmon Corporation, LLC
  • miRagen Therapeutics, Inc.
  • Peptinov SAS
  • Ribomic Inc.
  • Stratatech Corporation
  • Vida Therapeutics Inc.
  • VivaCell Biotechnology Espana S.L.

全身性硬皮症:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • abatacept
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • acALY-18
  • acetylcysteine
  • Aimspro
  • ANG-3070
  • ARG-201
  • belimumab
  • BL-1110
  • BOT-191
  • C-82
  • Cell Therapy for Dermatology and Immunology
  • disitertide
  • factor XIII (human)
  • FCX-013
  • GKT-831
  • GSK-2330811
  • IBIOCFB-03
  • IVA-337
  • JBT-101
  • KD-025
  • MGN-4220
  • nintedanib
  • Oligonucleotide for Scleroderma
  • onabotulinumtoxin A
  • PAT-048
  • PDX-002
  • PPV-06
  • RBM-006
  • riociguat
  • Small Molecule to Inhibit NFkB for Immunology and Oncology
  • Stem Cell Therapy for Crohns Disease, Systemic Sclerosis and Multiple Sclerosis
  • Synthetic Peptides to Inhibit TCR for Autoimmune Disorders and Dermatitis
  • tocilizumab
  • VCE-0048
  • VEDA-1209
  • VTI-1000 Series

全身性硬皮症治療藥:開發中產品的最新趨勢

全身性硬皮症治療藥:開發暫停的產品

全身性硬皮症治療藥:開發中止的產品

全身性硬皮症相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9540IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2017, provides an overview of the Systemic Sclerosis (Scleroderma) (Immunology) pipeline landscape.

Scleroderma is a group of rare diseases that involve the hardening and tightening of the skin and connective tissues. Symptoms include muscle pains, joint pain and swelling, ulcers occurring on fingertips, bloating of the tummy and diarrhea or constipation. Treatment includes antibiotic, pain relievers and immunosuppressant.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Systemic Sclerosis (Scleroderma) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Sclerosis (Scleroderma) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Sclerosis (Scleroderma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 5, 14, 5, 22 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Systemic Sclerosis (Scleroderma) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Sclerosis (Scleroderma) (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Systemic Sclerosis (Scleroderma) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Systemic Sclerosis (Scleroderma) (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Systemic Sclerosis (Scleroderma) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Sclerosis (Scleroderma) (Immunology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Systemic Sclerosis (Scleroderma) (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Systemic Sclerosis (Scleroderma) (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Systemic Sclerosis (Scleroderma) - Overview
    • Systemic Sclerosis (Scleroderma) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Systemic Sclerosis (Scleroderma) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Systemic Sclerosis (Scleroderma) - Companies Involved in Therapeutics Development
    • Allergan Plc
    • AnaMar AB
    • Angion Biomedica Corp
    • arGentis Pharmaceuticals LLC
    • Bayer AG
    • Biogen Inc
    • BLR Bio LLC
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Covis Pharmaceuticals Inc
    • CSL Ltd
    • Cumberland Pharmaceuticals Inc
    • F. Hoffmann-La Roche Ltd
    • Fibrocell Science Inc
    • GenKyoTex SA
    • Gilead Sciences Inc
    • GlaxoSmithKline Plc
    • iBio Inc
    • Inventiva
    • Leadiant Biosciences Inc
    • MedImmune LLC
    • Patagonia Pharmaceuticals LLC
    • PDX Pharmaceuticals LLC
    • Peptinov SAS
    • ProMetic Life Sciences Inc
    • Ribomic Inc
    • Samumed LLC
    • Sanofi
    • Seattle Genetics Inc
    • Stemline Therapeutics Inc
    • Stratatech Corp
    • Vicore Pharma AB
    • viDA Therapeutics Inc
    • VivaCell Biotechnology Espana SL
  • Systemic Sclerosis (Scleroderma) - Drug Profiles
    • abatacept - Drug Profile
    • acALY-18 - Drug Profile
    • ambrisentan - Drug Profile
    • anabasum - Drug Profile
    • ANG-3070 - Drug Profile
    • ARG-201 - Drug Profile
    • belimumab - Drug Profile
    • BLR-200 - Drug Profile
    • brentuximab vedotin - Drug Profile
    • C-1889 - Drug Profile
    • C-21 - Drug Profile
    • C-82 - Drug Profile
    • Cell Therapy for Dermatology and Immunology - Drug Profile
    • CM-101 - Drug Profile
    • dimethyl fumarate DR - Drug Profile
    • elapegademase - Drug Profile
    • factor XIII (human) - Drug Profile
    • FCX-013 - Drug Profile
    • GKT-831 - Drug Profile
    • GSK-2330811 - Drug Profile
    • IBIOCFB-03 - Drug Profile
    • ifetroban sodium - Drug Profile
    • IVA-337 - Drug Profile
    • M-10 - Drug Profile
    • MEDI-7734 - Drug Profile
    • miRNA-29 - Drug Profile
    • Monoclonal Antibodies to Antagonize IL-3RA for Autoimmune Disorders - Drug Profile
    • nintedanib - Drug Profile
    • nitroglycerin - Drug Profile
    • onabotulinumtoxinA - Drug Profile
    • PAT-048 - Drug Profile
    • PATS-03 - Drug Profile
    • PBI-4050 - Drug Profile
    • PBI-4425 - Drug Profile
    • PDX-002 - Drug Profile
    • PPV-06 - Drug Profile
    • RBM-006 - Drug Profile
    • riociguat - Drug Profile
    • rituximab biosimilar - Drug Profile
    • RP-182 - Drug Profile
    • SAR-100842 - Drug Profile
    • SAR-156597 - Drug Profile
    • SAR-317461 - Drug Profile
    • SM-04755 - Drug Profile
    • Small Molecule to Inhibit NFkB for Autoimmune Disorders, Melanoma and Inflammation - Drug Profile
    • Small Molecules to Antagonize 5-HT2B for Idiopathic Pulmonary Fibrosis and Systemic Sclerosis - Drug Profile
    • sodium nitrite SR - Drug Profile
    • Synthetic Peptides to Inhibit TCR for Autoimmune Disorders and Dermatitis - Drug Profile
    • terguride - Drug Profile
    • tocilizumab - Drug Profile
    • TRX-101 - Drug Profile
    • VCE-0048 - Drug Profile
    • VEDA-1209 - Drug Profile
    • VTI-1000 Series - Drug Profile
    • Wnt-001 - Drug Profile
  • Systemic Sclerosis (Scleroderma) - Dormant Projects
  • Systemic Sclerosis (Scleroderma) - Discontinued Products
  • Systemic Sclerosis (Scleroderma) - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Systemic Sclerosis (Scleroderma), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Systemic Sclerosis (Scleroderma) - Pipeline by Allergan Plc, H2 2017
  • Systemic Sclerosis (Scleroderma) - Pipeline by AnaMar AB, H2 2017
  • Systemic Sclerosis (Scleroderma) - Pipeline by Angion Biomedica Corp, H2 2017
  • Systemic Sclerosis (Scleroderma) - Pipeline by arGentis Pharmaceuticals LLC, H2 2017
  • Systemic Sclerosis (Scleroderma) - Pipeline by Bayer AG, H2 2017
  • Systemic Sclerosis (Scleroderma) - Pipeline by Biogen Inc, H2 2017
  • Systemic Sclerosis (Scleroderma) - Pipeline by BLR Bio LLC, H2 2017
  • Systemic Sclerosis (Scleroderma) - Pipeline by Boehringer Ingelheim GmbH, H2 2017
  • Systemic Sclerosis (Scleroderma) - Pipeline by Bristol-Myers Squibb Company, H2 2017
  • Systemic Sclerosis (Scleroderma) - Pipeline by Covis Pharmaceuticals Inc, H2 2017
  • Systemic Sclerosis (Scleroderma) - Pipeline by CSL Ltd, H2 2017
  • Systemic Sclerosis (Scleroderma) - Pipeline by Cumberland Pharmaceuticals Inc, H2 2017
  • Systemic Sclerosis (Scleroderma) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
  • Systemic Sclerosis (Scleroderma) - Pipeline by Fibrocell Science Inc, H2 2017
  • Systemic Sclerosis (Scleroderma) - Pipeline by GenKyoTex SA, H2 2017
  • Systemic Sclerosis (Scleroderma) - Pipeline by Gilead Sciences Inc, H2 2017
  • Systemic Sclerosis (Scleroderma) - Pipeline by GlaxoSmithKline Plc, H2 2017
  • Systemic Sclerosis (Scleroderma) - Pipeline by iBio Inc, H2 2017
  • Systemic Sclerosis (Scleroderma) - Pipeline by Inventiva, H2 2017
  • Systemic Sclerosis (Scleroderma) - Pipeline by Leadiant Biosciences Inc, H2 2017
  • Systemic Sclerosis (Scleroderma) - Pipeline by MedImmune LLC, H2 2017
  • Systemic Sclerosis (Scleroderma) - Pipeline by Patagonia Pharmaceuticals LLC, H2 2017
  • Systemic Sclerosis (Scleroderma) - Pipeline by PDX Pharmaceuticals LLC, H2 2017
  • Systemic Sclerosis (Scleroderma) - Pipeline by Peptinov SAS, H2 2017
  • Systemic Sclerosis (Scleroderma) - Pipeline by ProMetic Life Sciences Inc, H2 2017
  • Systemic Sclerosis (Scleroderma) - Pipeline by Ribomic Inc, H2 2017
  • Systemic Sclerosis (Scleroderma) - Pipeline by Samumed LLC, H2 2017
  • Systemic Sclerosis (Scleroderma) - Pipeline by Sanofi, H2 2017
  • Systemic Sclerosis (Scleroderma) - Pipeline by Seattle Genetics Inc, H2 2017
  • Systemic Sclerosis (Scleroderma) - Pipeline by Stemline Therapeutics Inc, H2 2017
  • Systemic Sclerosis (Scleroderma) - Pipeline by Stratatech Corp, H2 2017
  • Systemic Sclerosis (Scleroderma) - Pipeline by Vicore Pharma AB, H2 2017
  • Systemic Sclerosis (Scleroderma) - Pipeline by viDA Therapeutics Inc, H2 2017
  • Systemic Sclerosis (Scleroderma) - Pipeline by VivaCell Biotechnology Espana SL, H2 2017
  • Systemic Sclerosis (Scleroderma) - Dormant Projects, H2 2017
  • Systemic Sclerosis (Scleroderma) - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Systemic Sclerosis (Scleroderma) - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Systemic Sclerosis (Scleroderma), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top